Breaking News

Ajinomoto Althea Names CEO

By Kristin Brooks | January 6, 2014

Enloe to lead strategic growth efforts

J. David Enloe, Jr. has been appointed president and chief executive officer of Ajinomoto Althea Inc. Mr. Enloe will be responsible for developing strategies to support the company's growth efforts.
Mr. Enloe has more than 20 years of executive management experience, primarily in biotechnology, drug development, and GMP manufacturing. Most recently, he served as head of the Viral Therapeutics Business Unit at Lonza AG, which provides process development, scale-up and GMP manufacture of viral-based biologics. He was also the founder and chief executive officer of Vivante GMP Solutions, which he sold to Lonza in 2010. Prior to this, he was president and chief executive officer of Introgen Therapeutics.
"We are delighted to welcome David as the new leader of Ajinomoto Althea's management team," said Dr. Hiroshi Shiragami, co-chair of Ajinomoto Althea. "His unique depth of experience in the biotechnology industry, leadership abilities, financial management, manufacturing and contractual negotiation skills will be instrumental in supporting further expansion of our business."

blog comments powered by Disqus
  • CMC Biologics: Growing Through Innovation

    Tim Wright, Editor||January 28, 2016
    The new chief exec talks about industry trends and growth plans.

  • Cold-Chain Logistics & The Central Lab

    Kristin Brooks, Associate Editor||January 28, 2016
    Eric Hayashi of LabConnect discusses safety measures to ensure sample integrity

  • A Look at DCAT Week ‘16

    Tim Wright, Editor||January 28, 2016
    On the pulse of the pharmaceutical manufacturing value chain, DCAT Week ‘16 will deliver top-flight education programs and networking events.